Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry.
Brioli A, Lomaia E, Fabisch C, Sacha T, Klamova H, Morozova E, Golos A, Ernst P, Olsson-Stromberg U, Zackova D, Nicolini FE, Bao H, Castagnetti F, Patkowska E, Mayer J, Hirschbühl K, Podgornik H, Paczkowska E, Parry A, Ernst T, Voskanyan A, Szczepanek E, Saussele S, Franke GN, Kiani A, Faber E, Krause S, Casado LF, Lewandowski K, Eder M, Anhut P, Gil J, Südhoff T, Hebart H, Heibl S, Pfirrmann M, Hochhaus A, Lauseker M. Brioli A, et al. Among authors: zackova d. Leukemia. 2024 May;38(5):1072-1080. doi: 10.1038/s41375-024-02204-y. Epub 2024 Mar 28. Leukemia. 2024. PMID: 38548962 Free PMC article.
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia.
Pfirrmann M, Clark RE, Prejzner W, Lauseker M, Baccarani M, Saussele S, Guilhot F, Heibl S, Hehlmann R, Faber E, Turkina A, Ossenkoppele G, Höglund M, Zaritskey A, Griskevicius L, Olsson-Strömberg U, Everaus H, Koskenvesa P, Labar B, Sacha T, Zackova D, Cervantes F, Colita A, Zupan I, Bogdanovic A, Castagnetti F, Guilhot J, Hasford J, Hochhaus A, Hoffmann VS. Pfirrmann M, et al. Among authors: zackova d. Leukemia. 2020 Aug;34(8):2138-2149. doi: 10.1038/s41375-020-0931-9. Epub 2020 Jun 29. Leukemia. 2020. PMID: 32601376 Free PMC article.
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib.
Machova Polakova K, Albeer A, Polivkova V, Krutska M, Vlcanova K, Curik N, Fabarius A, Klamova H, Spiess B, Waller CF, Brümmendorf TH, Dengler J, Kunzmann V, Burchert A, Belohlavkova P, Mustjoki S, Faber E, Mayer J, Zackova D, Panayiotidis P, Richter J, Hjorth-Hansen H, Kamińska M, Płonka M, Szczepanek E, Szarejko M, Bober G, Hus I, Grzybowska-Izydorczyk O, Wasilewska E, Paczkowska E, Niesiobędzka-Krężel J, Giannopoulos K, Mahon FX, Sacha T, Saußele S, Pfirrmann M. Machova Polakova K, et al. Among authors: zackova d. Leukemia. 2024 Feb;38(2):318-325. doi: 10.1038/s41375-023-02109-2. Epub 2023 Dec 21. Leukemia. 2024. PMID: 38129513 Free PMC article.
Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.
Hoffmann VS, Baccarani M, Hasford J, Castagnetti F, Di Raimondo F, Casado LF, Turkina A, Zackova D, Ossenkoppele G, Zaritskey A, Höglund M, Simonsson B, Indrak K, Sninska Z, Sacha T, Clark R, Bogdanovic A, Hellmann A, Griskevicius L, Schubert-Fritschle G, Sertic D, Guilhot J, Lejniece S, Zupan I, Burgstaller S, Koskenvesa P, Everaus H, Costeas P, Lindoerfer D, Rosti G, Saussele S, Hochhaus A, Hehlmann R. Hoffmann VS, et al. Among authors: zackova d. Leukemia. 2017 Mar;31(3):593-601. doi: 10.1038/leu.2016.246. Epub 2016 Aug 29. Leukemia. 2017. PMID: 27568522
Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin.
Lauseker M, Bachl K, Turkina A, Faber E, Prejzner W, Olsson-Strömberg U, Baccarani M, Lomaia E, Zackova D, Ossenkoppele G, Griskevicius L, Schubert-Fritschle G, Sacha T, Heibl S, Koskenvesa P, Bogdanovic A, Clark RE, Guilhot J, Hoffmann VS, Hasford J, Hochhaus A, Pfirrmann M. Lauseker M, et al. Among authors: zackova d. Am J Hematol. 2019 Nov;94(11):1236-1243. doi: 10.1002/ajh.25628. Epub 2019 Sep 14. Am J Hematol. 2019. PMID: 31456269 Free article.
Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission.
Machova Polakova K, Zizkova H, Zuna J, Motlova E, Hovorkova L, Gottschalk A, Glauche I, Koblihova J, Pecherkova P, Klamova H, Stastna Markova M, Srbova D, Benesova A, Polivkova V, Jurcek T, Zackova D, Mayer J, Ernst T, Mahon FX, Saussele S, Roeder I, Cross NCP, Hochhaus A. Machova Polakova K, et al. Among authors: zackova d. Leukemia. 2020 Aug;34(8):2113-2124. doi: 10.1038/s41375-020-0882-1. Epub 2020 May 29. Leukemia. 2020. PMID: 32472084
Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice.
Zackova D, Klamova H, Belohlavkova P, Stejskal L, Necasova T, Semerad L, Weinbergerova B, Srbova D, Voglova J, Cicatkova P, Sustkova Z, Hornak T, Baranova J, Prochazkova J, Mayer J. Zackova D, et al. Leuk Lymphoma. 2021 Jan;62(1):194-202. doi: 10.1080/10428194.2020.1827242. Epub 2020 Oct 6. Leuk Lymphoma. 2021. PMID: 33021423
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy.
Salmon M, White HE, Zizkova H, Gottschalk A, Motlova E, Cerveira N, Colomer D, Coriu D, Franke GN, Gottardi E, Izzo B, Jurcek T, Lion T, Schäfer V, Venturi C, Vigneri P, Zawada M, Zuna J, Hovorkova L, Koblihova J, Klamova H, Markova MS, Srbova D, Benesova A, Polivkova V, Zackova D, Mayer J, Roeder I, Glauche I, Ernst T, Hochhaus A, Polakova KM, Cross NCP. Salmon M, et al. Among authors: zackova d. Leukemia. 2022 Jul;36(7):1879-1886. doi: 10.1038/s41375-022-01612-2. Epub 2022 Jun 8. Leukemia. 2022. PMID: 35676453 Free PMC article.
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF.
Žáčková D, Semerád L, Faber E, Klamová H, Stejskal L, Bělohlávková P, Karas M, Cmunt E, Černá O, Procházková J, Čičátková P, Kvetková A, Horňák T, Skoumalová I, Srbová D, Šálek C, Buffa D, Voglová J, Jurček T, Folta A, Ježíšková I, Žižková H, Machová Poláková K, Papajík T, Žák P, Jindra P, Svobodník A, Štěpánová R, Mayer J. Žáčková D, et al. Leukemia. 2024 Apr;38(4):893-897. doi: 10.1038/s41375-024-02215-9. Epub 2024 Mar 12. Leukemia. 2024. PMID: 38472478 Free PMC article. No abstract available.
Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.
Zackova D, Klamova H, Muzik J, Cmunt E, Racil Z, Machova Polakova K, Dvorakova D, Jurcek T, Razga F, Cetkovsky P, Dusek L, Mayer J. Zackova D, et al. Leuk Lymphoma. 2013 Oct;54(10):2310-3. doi: 10.3109/10428194.2013.772173. Epub 2013 Feb 28. Leuk Lymphoma. 2013. PMID: 23373966 No abstract available.
49 results